We appreciate the comments from Brutsaert and De Keulenaer 1 on our recent publication on the ventricular and vascular effects of sildenafil in people with heart failure with preserved ejection fraction enrolled in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial.
Correspondence
We appreciate the comments from Brutsaert and De Keulenaer 1 on our recent publication on the ventricular and vascular effects of sildenafil in people with heart failure with preserved ejection fraction enrolled in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial. 2, 3 The authors suggest that different results might have been observed had heart failure with preserved ejection fraction subjects been subgrouped according to characteristics, such as age, sex, body composition, and comorbidities. We agree that this concept has merit, but many or most of these characteristics coexist within the typical heart failure with preserved ejection fraction patient, and although the comorbid conditions influence cardiovascular properties, fundamental disease-specific changes have been shown to underlie heart failure with preserved ejection fraction, irrespective of comorbidities. 4 Brutsaert and De Keulenaer 1 make the point that changes in arterial afterload can affect ventricular function, going on to suggest that reduction in arterial wave reflections might have affected the timing of relaxation to cause or contribute to the observed decrease in peak ventricular pump performance. This is an intellectually appealing theory, but our data do not support it. There was no effect of sildenafil on wave reflections, assessed by aortic augmentation index, and there was no effect of sildenafil on left ventricular relaxation, at least as estimated by left ventricular diastolic tissue velocities. 2 Therefore, we are not convinced that changes in loading sequence completely explain the findings in our study.
The authors further suggest that a lower sildenafil dose might have been more effective. This was not observed at the 20-mg dosage, 2 although lower doses were not examined in the RELAX trial. 3 Stroke work and peak power are both independent of afterload but vary directly with preload (end diastolic volume). 5 Because both were divided by end-diastolic volume, these indices can be considered as measures of ventricular contractility, 5 
